A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 10 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
- 19 Apr 2011 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov.
- 03 Jun 2009 Interim results presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).